scribe

Winter 2002 - Volume 13, No. 1

current issue | past issues | alum notes | contact info | home

Articles
WSU Recognized as Founding Member of AAMC

 

New Curriculum Addresses Aging and Geriatrics

 

Providing Answers About Viruses and Drug Resistance

 

Publication Shows Gene Programming is Coming Soon

 

Antacids May be More Important than Calcium in Osteoporosis Prevention

 

Congressman Rallies for Graduate Medical Education

 

Tracking Software Evaluates Students' Clinical Rotations

 

Prayer and Fellowship Promote Healthy Outcomes

 

Diabetes Program Participants See Sharp Drop in Risk Factors

 

Master's Degree Offered in Genetic Counseling

 

Influenza Vaccine Research Targets Large Capacity Virus

 

WSU School of Medicine Recognizes Excellence in Medical Student Research

 

In Memory of Professor Emeritus Maurice Bernstein

 

School Begins Multi-Million dollar Energy Savings Project

 

WSU Establishes Metabolic Research Center Dedicated to Diabetes/Obesity Research

 

Drug Delivery System Uses Liposomes to Treat Ocular Tumors

 

Dr. Goodman Receives Lifetime Achievement Award from American Association of Physical Anthropologists

 

Medical Students Learn and Practice Professionsl Values

 

Leukemia Drug Gets Priority Approval

 

Psychiatry Students Awarded for Research

 

Lower Cardiovascular Risk is Added Benefit of Exercise

 

$5 Million Grant Partners WSU and Florida A&M for Environmental Health Research

 

Graduates Earn PhDs

Influenza Vaccine Research Targets Large Capacity Virus


Dr. Roberts has been recognized by the NIAID for his work on flu vaccines and viruses.

Getting a bullet to hit a target isn’t easy; but a bigger target could certainly increase your chances. So it goes with Dr. Chris Roberts and his search for influenza vaccines. The virus he studies is the filamentous version, which is roughly 250 times longer than normal spherical viruses. In simple terms, the spherical virus looks like a ball and the filamentous version is more like a bat or rod. “This large capacity to store genetic material makes the virus more dangerous, but it’s a good candidate for a vaccine by the same reasoning,” Dr. Roberts said.

With a five-year $800,000 grant from the National Institute of Allergy and Infectious Diseases (NIAID), Dr. Roberts is investigating the cell biology of virus entry and assembly mechanisms related to the filamentous influenza virus. It’s his hunch that the huge virus is more pathogenic, because more antibodies may be required to neutralize it. Furthermore, in comparison to typical, spherical viruses that often have missing RNA segments, the filamentous version contains extra copies of viral RNA, increasing its odds of becoming infectious.

Using three-dimensional digital imaging microscopy, Dr. Roberts and his research team in the Department of Immunology and Microbiology are documenting the mechanisms and movement of this virus-type. Its predominance in human influenza virus samples suggests that it may play an active role in spreading disease. Dr. Roberts explains that its elongated body may bridge the gaps between cells, allowing newly formed viruses to go directly from one host cell to the next. This might allow the virus to escape normal immune defense mechanisms.

The influenza virus, which causes the common flu, is continually undergoing subtle genetic mutations, allowing new strains to develop and infect people who might otherwise be immune by prior infection or vaccination. The NIAID has given special recognition to the work done by Dr. Roberts, as it tries to support and design more effective flu vaccines and treatments.

State of the School

Welcome New Faculty

Notes

Honors

Rounds

Continuing Medical Education

Credits